Jail for Off-Label Promotion?

July 2011
Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p11
The article focuses on the move of federal prosecutors to seek jail time for four executives of Pennsylvania-based Synthes who have pleaded guilty to a misdemeanor involving the off-label use of a bone cement product.


Related Articles

  • Bad Medicine. Smauel Rocque, Anslem // Jet;8/20/2012, Vol. 121 Issue 17, p17 

    The article focuses on an investigation of drug manufacturer GlaxoSmithKline (GSK) concerning the company's bribery of physicians to prescribe its products when they were not needed. It states that drugs improperly marketed by GSK include Avandia toward diabetics and PAXIL as an antidepressant...

  • Speak Out. Wright, David; Avallone, Anthony N.; Berger, Aaron; Wrenn, John // Urology Times;4/1/2009, Vol. 37 Issue 4, p30 

    The article presents answers to a question on whether pharmaceutical companies be allowed to market pharmaceutical products for off-label use.

  • Off-Label Drug Uses. . Generali, Joyce A.; Cada, Dennis J. // Hospital Pharmacy;Mar2010, Vol. 45 Issue 3, p208 

    This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This...

  • SLEEPING PILLS. Hanau, Michael S. // Primary Psychiatry;May2008, Vol. 15 Issue 5, p23 

    A letter to the editor is presented in response to an article by Milton K. Erman which critiques the popularity of trazodone and other non-benzodiazepine analogs for off-label use.

  • Perspective on 'Off-Label'.  // Review of Optometry;5/15/2012 Clinical Guide to Ophtha, p22A 

    The article offers perspectives on the off-label use of approved medications which is considered as a legal and necessary part in the practice of medicine for optimal patient care.

  • Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter. Duran-Garcia, Esther; Santos-Ramos, Bernardo; Puigventós-Latorre, Francesc; Ortega, Ana // International Journal of Clinical Pharmacy;Sep2011, Vol. 33 Issue 5, p722 

    A response by authors including Ana Ortega, Bernardo Santos-Ramos and Esther Duran-Garcia to the letter to the editor about an article on regulation of "off-label" consumption of drugs in hospitals is presented.

  • Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use. Vargas-Rivas, Jaime; Sabater-Hernández, Daniel; Calleja-Hernández, Miguel; Faus, María; Martínez-Martínez, Fernando // International Journal of Clinical Pharmacy;Sep2011, Vol. 33 Issue 5, p719 

    A letter to the editor is presented in response to an article on the actions taken by the Pharmacy and Therapeutics Committee in identifying and controlling "off-label" drug consumption in medical facilities.

  • Používání léků mimo schválené indikace v pediatrii. Langerová, P.; Urbánek, K. // Czecho-Slovak Pediatrics / Cesko-Slovenska Pediatrie;Dec2011, Vol. 66 Issue 6, p380 

    No abstract available.

  • Tranexamic acid -- NICE's first off-label evidence summary.  // PharmacoEconomics & Outcomes News;10/27/2012, Issue 665, p11 

    The article reports that an evidence summary for off-label use of a drug backing the tranexamic acid for haemorrhage has been released by the National Institute for Health and Clinical Excellence (NICE) in Great Britain.


Read the Article


Sign out of this library

Other Topics